계명대학교 의학도서관 Repository

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

Metadata Downloads
Author(s)
Sang Eun YoonYuqin SongSeok Jin KimDok Hyun YoonTsai-Yun ChenYoungil KohKa Won KangHo Sup LeeKevin Kuang Wei TaySoon Thye LimMichele PoonCosphiadi IrawanWeili ZhaoYoung Rok DoMark Hong LeeSoo Chin NgWon-Sik LeeYe GuoHuilai ZhangHye Jin KangHwan Jung YunHyo Jung KimDaryl Tan Chen LungJae-Yong KwakJae Joon HanYeung-Chul MunSung Yong OhHyeok ShimJung Hye KwonByeong Seok SohnSeong Kyu ParkJae-Cheol JoYoung Hyeh KoZhu JunWon Seog Kim
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Lancet Reg Health West Pac
Issued Date
2021
Volume
10
Keyword
LymphomaT-CellPeripheralExtranodal NK-T-CellFrequencyTherapeuticsSurvivalPrognosis
Abstract
Background:
Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is regionally heterogeneous. Several studies have been conducted to evaluate the clinical features and treatment outcomes of this disease entity, but the majority of these were conducted in limited areas, making it difficult to comprehensively analyze their relative frequency and clinical features. Furthermore, no consensus treatment for PTCLs has been established. Therefore, we conducted an Asia-specific study to understand the relative frequency of PTCLs and assess treatments and their outcomes in Asian patients.

Methods:
We performed a multinational, multicenter, prospective registry of adult patients with PTCLs that was named as the International Cooperative non-Hodgkin T-cell lymphoma prospective registry study where thirty-two institutes from six Asian countries and territories (Korea, China, Taiwan, Singapore, Malaysia, and Indonesia) participated.

Findings:
A total of 486 patients were registered between April 2016 and February 2019, and more than a half of patients (57%) had stage III or IV. Extranodal natural killer (NK)/T- cell lymphoma was the most common subtype (n = 139,28.6%), followed by angioimmunoblastic T-cell lymphoma (AITL, n = 120,24.7%), PTCL-not otherwise specified (PTCL-NOS, n = 101,20.8%), ALK-positive anaplastic large cell lymphoma (ALCL, n = 34,6.9%), and ALK-negative ALCL (n = 30,6.2%). The median progression-free survival (PFS) and overall survival (OS) were 21.1 months (95% CI,10.6–31.6) and 83.6 months (95% CI, 56.7–110.5), respectively. Upfront use of combined treatment with chemotherapy and radiotherapy showed better PFS than chemotherapy alone in localized ENKTL whereas consolidation with upfront autologous stem cell transplantation (SCT) provided longer PFS in advance stage ENKTL. In patients with PTCLs other than ENKTL, anthracycline-containing chemotherapies were widely used, but the outcome of those regimens was not satisfactory, and upfront autologous SCT was not significantly associated with survival benefit, either. The treatment outcome of salvage chemotherapy was disappointing, and none of the salvage strategies showed superiority to one another.

Interpretation:
This multinational, multicenter study identified the relative frequency of each subtype of PTCLs across Asian countries, and the survival outcomes according to the therapeutic strategies currently used.

Funding:
Samsung Biomedical Research Institute
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine (의과대학)
Citation
Sang Eun Yoon et al. (2021). Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. Lancet Reg Health West Pac, 10, 100126. doi: 10.1016/j.lanwpc.2021.100126
Type
Article
ISSN
2666-6065
Source
https://www.sciencedirect.com/science/article/pii/S2666606521000353
DOI
10.1016/j.lanwpc.2021.100126
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43719
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.